Children with sickle cell anemia have an increased susceptibility to bacterial infections, especially to those caused by Streptococcus pneumoniae. We therefore conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial to test whether the regular, daily administration of oral penicillin would reduce the incidence of documented septicemia due to S.pneumoniae in children with sickle cell anemia who were under the age of three years at the time of entry. The children were randomly assigned to receive either 125 mg of penicillin V potassium (105 children) or placebo (110 children) twice daily. The trial was terminated 8 months early, after an average of 15 months of follow-up, when an 84 percent reduction in the incidence of infection was observed in the group treated with penicillin, as compared with the group given placebo (13 of 110 patients vs. 2 of 105; P = 0.0025), with no deaths from pneumococcal septicemia occurring in the penicillin group but three deaths from the infection occurring in the placebo group. On the basis of these results, we conclude that children should be screened in the neonatal period for sickle cell hemoglobinopathy and that those with sickle cell anemia should receive prophylactic therapy with oral penicillin by four months of age to decrease the morbidity and mortality associated with pneumococcal septicemia.

No abstract

Twenty-four hours after injection of 0.5 mg/kg HPPH, tumor-to-brain drug ratios ranged from 5:1 to 15:1. Enhanced survival was observed in each of the HPPH/PDT-treated animal groups. These data suggest that HPPH may be a useful adjuvant for the treatment of malignant gliomas.

Point mutations in G gamma and A gamma globin gene promoters are associated with increased production of G gamma and A gamma globin, respectively. To determine whether an upstream promoter mutation could account for elevated A gamma in a Black adolescent with A gamma-beta+-HPFH and sickle cell trait, we cloned the 13 kb BglII fragment containing both gamma genes into phage lambda vector EMBL3. For one clone, the A gamma upstream promoter showed no hybridization to a 19 bp oligonucleotide whose sequence centered at -117. A gamma promoter sequence data for this mutant clone revealed a 13 bp deletion which eliminated the A gamma distal CCAAT box. Amplified A gamma genomic DNA of this and a similar case showed hybridization to both deletion-mutant and normal oligonucleotide probes. We propose that this 13 bp deletion removes part of the binding site for a repressor protein which is abundant in adult erythroid cells.

No abstract

A 6-year-old boy on maintenance chemotherapy for acute lymphocytic leukemia developed severe hypoplastic anemia during chemotherapy previously well tolerated. The hypoplastic episode persisted for approximately 30 days. Human parvovirus (B19), the etiologic agent of aplastic crisis in persons with underlying hemolytic syndromes, was detected in the patient's serum 25-30 days after onset of hemoglobin decrease, and B19 IgM seroconversion occurred 1 week later. The patient's hypoplastic anemia was presumably caused by prolonged B19 infection resulting from a blunted immune response. An immune response to the B19 infection and resolution of the illness were temporally associated with brief cessation of chemotherapy.

Two groups of children with refractory acute lymphoblastic leukemia were treated with a regimen of methotrexate (MTX) and asparaginase (Asn'ase) based on studies of the effect of MTX in vitro on human lymphoblasts exposed to Asn'ase. Induction therapy in 12 children produced 4 complete remissions, 3 partial remissions, and 5 failures. Responsiveness to Asn'ase seemed necessary for successful induction with the drug combination. Maintenance therapy in 18 children produced a median hematologic remission of 31 weeks (range 3-85 weeks). During remission, 2 children developed central nervous system leukemia and 2 died of infection. The mean maximally tolerated dose of MTX was 361 mg/m2. The results of this trial suggest therapeutic synergy in maintenance therapy and the capability of Asn'ase to attenuate MTX toxicity.Cancer 43:1089-1094, 1979. H E USE OF MULTIPLE CHEMOTHERAPEUTICT AGENTS is superior to single agent therapy in the management of acute lymphoblastic leukemia (ALL) of childhood, and has contributed significantly to the improved prognosis in that disease Certain pharmacologic considerations make methotrexate (MTX) and asparaginase (Asn'ase) attractive for such combination chemotherapy. Asn'ase seems to lack crossresistance with other antileukemic drugs, and has a rather unique spectrum of toxicity." Response to MTX varies significantly with manipulation of dosage and ~chedule,'~-'~~*' allowing comparison of multiple regimens of MTX plus another chemotherapeutic agent. In addition, the mechanisms of action of MTX and Asn'ase may interact. Although MTX is a known folate antagonist, its final mechanism of cell death is ~n c l e a r .~ One factor appears to be continued synthesis of RNA and protein with concomitant inhibition of nuclear DNA replication, a phenomenon termed "unbalanced g r~w t h . "~ When the drugs are used together, Asn'ase may attenuate MTX effect through inhibition of protein synthesis, thus altering the unbalanced growth induced by MTX.8 Asn'ase can also have an inhibitory effect on MTX membrane transport.23,32 A goal of combined therapy with these two drugs then becomes an additive or synergistic cytotoxic effect on leukemic cells, with an accompanying attenuation of, or "rescue" from, the usual toxic manifestations of MTX on bone marrow and mucosal surfaces.This schedule-dependent synergistic cytotoxic effect with MTX and Asn'ase has been demonstrated on murine leukemia cells both in vitro and in vivo,6*8,12,31 and in human leukemia cells in v i t r~. ' ,~ Capizzi studied the effect of MTX on the rate of DNA synthesis in vztro in human lymphoblasts obtained from peripheral blood and bone marrow, before and after a single intravenous dose of A s n ' a~e .~-~ He showed that within 24 hours of an exposure to Asn'ase the rate of DNA synthesis

Two approaches were used to demonstrate that reduction in serum opsonization of Streptococcus pneumoniae via the alternative complement pathway in children with sickle cell disease is related to a deficiency of antibodies to pneumococcal capsular polysaccharide. First, opsonization of S. pneumoniae mediated by the alternative pathway in patients' sera was restored to normal by addition of the purified IgG or IgM fraction of goat antiserum to capsular polysaccharide of the homologous serotype. Secondly, IgG antibody titers to capsular polysaccharide in patients' sera correlated significantly with alternative pathwaymediated opsonization; the correlation between titers of IgM anticapsular antibodies and opsonization approached statistical significance. The sum of the IgG and IgM anticapsular antibody titers correlated most significantly with opsonization. Our results suggest that reduction in alternative pathway-mediated opsonization in sera from children with sickle cell disease is related to low levels of both IgG and IgM anticapsular antibodies.